Comprehensive Overview of Pain Biologics, Steroids & Hyaluronic Acid in Pain Medicine

PAIN BIOLOGICS, STEROIDS & HYALURONIC ACID
PRP, BMAC, Exosomes, Nanofat, SVF, Stem Cell Therapy - Preparation, Dosage, Safety & Evidence
Dr. Smrutirekha Hota
MD, FIPP, CIPS, EDPM, FIPM
Consultant Pain & Spine Physician - JSR Pain Hospital | Daradia Pain Clinic, Kolkata | Zenith Cardiac & Super Speciality Hospital
An Educational Overview for Pain Medicine Fellows

ROADMAP
What You Will Learn Today
1
Pain Biologics - The Full Toolkit
PRP, BMAC, exosomes, nanofat, adipose-derived cells, SVF, and cultured stem cell
therapy (Ciplostem).
2
Preparation, Dosage & Safety
How each biologic is prepared, typical dose/volume ranges, and precautions to
counsel patients on.
3
Literature-Based Overviews
Key findings from recent published studies for each biologic, presented as clinical
overviews.
4
Steroids & Hyaluronic Acid
Mechanism, dosing by site, technique, and safety for the two most established
injectables.
5
An Integrated Teaching Takeaway
How biologics, steroids, and HA fit together in real practice.
Dr. Smrutirekha Hota | MD, FIPP, CIPS, EDPM, FIPM | Fellow Teaching Session 1

PAIN BIOLOGICS
The Regenerative Paradigm: Core Concepts
1
Growth Factors
Concentrated PDGF, TGF-b, VEGF and IGF-1
drive angiogenesis and collagen synthesis
at the injury site.
2
Cellular Signalling
Mesenchymal cells migrate to injury sites
and differentiate along tissue-specific lines
under local cues.
3
Immunomodulation
Paracrine signals shift the local
environment from pro-inflammatory
toward a reparative phenotype.
4
Cell-Free Signalling
Exosomal and secretome cargo (microRNA,
proteins) can transmit regenerative
instructions without transplanting cells.

PRP
Platelet-Rich Plasma: Definition & Classes
Autologous blood centrifuged to concentrate platelets 3-5x above baseline, delivering a supraphysiologic dose of
growth factors to the injury site.
Class Leukocyte Content
LR-PRP (Leukocyte-Rich) High WBC - tendinopathy
LP-PRP (Leukocyte-Poor) Minimal WBC - intra-articular OA
PRF (fibrin) Variable - sustained release
CLINICAL PEARL Teaching rule of thumb: LP-PRP for joints (minimizes inflammatory flare), LR-PRP for tendons (a controlled inflammatory trigger aids remodelling).

PRP
PRP: Classification Systems
Two frameworks are widely used to standardize how PRP products are described and compared across studies.
PAW System (Platelet count / Activation / White cells)
Code Meaning
P1 / P2 / P3 Platelet count: below baseline / 0-750,000 per uL / 750,000-1,250,000 per uL
X vs – (dash) Exogenous activation (calcium/thrombin) vs no activation
A vs B WBC count above baseline (A) vs below baseline (B)
α vs β Neutrophil count above (α) vs below (β) baseline
Example notation: P2XBβ (moderate platelet count, exogenously activated, low WBC, low neutrophil)
Mishra Classification
• Four base types: Leukocyte-Rich Non-Activated, Leukocyte-Rich Activated, Leukocyte-Poor Non-Activated, Leukocyte-Poor Activated
• Each further sub-typed as (A) >5x baseline platelet concentration or (B) <5x baseline platelet concentration

PRP
PRP: Growth Factors & Mechanism of Action
1
Platelets are activated exogenously (calcium chloride/thrombin) or endogenously (contact with exposed collagen at the injury site)
2
Alpha-granules degranulate, releasing PDGF, TGF-β1, IGF-1, VEGF, EGF, and FGF into the local tissue environment
3
Growth factors bind transmembrane receptors on MSCs, fibroblasts, osteoblasts, and endothelial cells, activating internal signalling cascades
4
Downstream effects: chemotaxis, angiogenesis, cell proliferation/differentiation, collagen and extracellular matrix synthesis
5
Platelets also release IL-1 receptor antagonist, which inhibits NF-κB-driven apoptotic signalling — a further anti-inflammatory contribution
CLINICAL PEARL IGF-1, together with PDGF and TGF-β1, stimulates synovial fibroblasts to synthesize more endogenous hyaluronic acid — a direct biological link between PRP and the HA
physiology discussed earlier in this session.

PRP
PRP: Preparation, Dosage & Safety
Preparation Protocol
Prep: Draw 10-60 mL autologous venous blood into ACD-A anticoagulated tubes. Single or double centrifugation spin (typically 1500-2000 rpm) separates red cells from the platelet-rich plasma/buffy
coat layer. Optional activation with calcium chloride or autologous thrombin just before injection.
Dose/Volume: Final injectate volume typically 3-8 mL depending on target (small joint/tendon 2-4 mL; knee 5-8 mL; intradiscal 1-2 mL). Platelet concentration goal: 3-5x baseline.
Precaution: Confirm no active infection or anticoagulant therapy that cannot be safely held; avoid NSAIDs 3-5 days before and after the procedure.
Parameter Detail
Typical course 1-3 sessions, spaced 4-6 weeks apart
Needle gauge 22-25G under ultrasound guidance
Contraindications Active infection, platelet dysfunction/thrombocytopenia, sepsis, malignancy at injection site

PRP
PRP: Equipment & Centrifugation Science
Standard setup to produce ~4 mL of PRP from a 20 mL blood draw:
• Centrifuge — temperature-regulated preferred over ambient/normal
• 20 mL collection tubes (x2) with ACD-A anticoagulant, 9:1 blood-to-anticoagulant ratio
• 18-gauge blunt-tip transfer needles (x2) and a 20 mL syringe
• Two accepted pathways: the classic PRP double-spin method, or the single high-speed buffy coat method
Relative Centrifugal Force (RCF) Formula
g Force (RCF) = (RPM)² × 1.118 × 10⁻⁵ × r
RPM = √[RCF / (r × 1.118)] × 10⁵ where r = rotor radius (cm)

PRP
PRP: Pre/Post-Procedure Protocol & Effectiveness Timeline
Before the Procedure
• No heavy meal in the 2 hours before blood collection
• Drink 500-750 mL water beforehand
• 5-7 minutes of light walking before the draw
• Minimize tourniquet time as much as possible
After the Procedure
• No NSAIDs and/or steroids for 7-10 days post-injection
• Normal activity only — no extra exercise for 48-72 hours
• After 10-12 days, begin light isometric exercise; avoid stressful loading for 6 weeks
• Tendons, ligaments, and bursae often respond before joints do
Effectiveness Timeline
• No immediate pain relief — onset is typically delayed 3-4 weeks
• Improvement continues progressively over 3-6 months post-injection
• Reported recovery windows vary widely across studies — 3, 6, and even 12 months have all been described
CLINICAL PEARL Set patient expectations at the first visit: PRP is a slow-building therapy, not a same-day fix — counsel accordingly to avoid early disappointment.

PRP
PRP: Overview from the Recent Literature
Song I, et al. Orthop J Sports Med. 2025.
In a knee OA cohort, 72% of PRP responders achieved at least a 20% pain reduction at 12
weeks; response was not reliably predicted by age, BMI, or radiographic grade.
Advancements in Regenerative Therapies review. PMC. 2025.
Across 20 included PRP studies (2009-2025), PRP showed consistent pain-reduction and
functional-recovery signal, though preparation protocols varied widely.
Pham GM. J Clin Med. 2025;14:6959.
A narrative review of PRP and BMAC in ACL reconstruction found both offer measurable
augmentation benefit, with BMAC contributing an additional cellular component.
Head-to-head PRP vs hyaluronic acid trial (2025).
PRP produced significantly greater VAS pain improvement than HA at 24 weeks in knee OA
(38.5 vs 18.7 points).

PRP
PRP: Indications & Clinical Pearls
• Knee osteoarthritis (mild-moderate)
• Lateral & medial epicondylitis
• Rotator cuff tendinopathy
• Plantar fasciitis
• Discogenic low back pain (selected, intradiscal)
Clinical Pearls
• Ultrasound guidance for accurate deposition
• Avoid NSAIDs before/after injection
• Counsel patients: ~1 in 5 will not respond meaningfully
• A course of 1-3 sessions is often more realistic than a single shot

BMAC
Bone Marrow Aspirate Concentrate (BMAC)
• Harvested from the posterior iliac crest under local anaesthesia
• Centrifuged at the point of care to concentrate nucleated cells and platelets
• Contains a heterogeneous mix - MSCs, hematopoietic cells, growth factors - not a pure stem-cell product
• Delivers both a cellular and growth-factor payload in a single autologous injection
CLINICAL PEARL Think of BMAC as 'PRP plus marrow-derived cells' - reserved for indications where cartilage or disc regeneration, not just anti-inflammatory effect, is the goal.

BMAC
BMAC: Preparation, Dosage & Safety
Prep: Aspirate 30-60 mL bone marrow from the posterior iliac crest under local anaesthesia (multiple small-volume draws from different sites/depths improve cellular yield). Centrifuge at the point of
care to concentrate nucleated cells, yielding a final volume of roughly 3-10 mL.
Dose/Volume: Injection volume typically 3-6 mL depending on target (intradiscal 1-2 mL; facet/SI joint 1-3 mL; larger joint 4-6 mL).
Precaution: Marrow-harvest site discomfort is common and often exceeds discomfort at the injection site - counsel patients specifically.
Parameter Detail
Harvest site Posterior superior iliac spine (PSIS), under local anaesthesia
Typical course Usually a single session; repeat only after re-assessment
Contraindications Active infection, coagulopathy, hematologic malignancy, anticoagulation not optimized

BMAC
BMAC: Overview from the Recent Literature
ASIPP 2025 Guideline Update.
Lumbar intradiscal and epidural BMAC injections are supported by fair-quality evidence, with
a consensus-based moderate recommendation for chronic low back pain.
Pham GM. J Clin Med. 2025;14:6959.
Comparing PRP and BMAC, BMAC's marrow-derived cellular fraction was associated with
additional reparative signal in tendon and ligament healing models.
Multispecialty Working Group Consensus. 2025.
BMAC is categorized among 'minimally manipulated' point-of-care biologics, giving it a more
favourable regulatory pathway than culture-expanded products.
General pain biologics literature synthesis, 2025.
BMAC shows a favourable safety profile with the marrow-harvest site accounting for most
reported minor procedural discomfort.

BMAC
BMAC: Indications & Clinical Pearls
Intradiscal Injection
Selected discogenic low back pain, aiming to influence the degenerated disc environment.
Facet & SI Joint
Alternative or adjunct to PRP where a regenerative goal is prioritized.
Cartilage Defects
Combined with surgical technique (e.g., microfracture augmentation) in selected settings.
Non-union / Delayed Union
Orthopedic use to support bone healing at a fracture site.
CLINICAL PEARL The marrow-harvest site often causes more transient discomfort than the target injection itself - counsel patients before the procedure.

EXOSOMES
Exosomes: The Cell-Free Frontier
No Live Cells Transplanted
Extracellular vesicles (30-150 nm) carry microRNA and protein cargo without transferring living cells.
Paracrine Messaging
Reprogram recipient cells toward an anti-inflammatory, pro-regenerative phenotype.
The MSC Secretome
Exosomes are one component of the broader MSC secretome - the full set of bioactive molecules cells secrete.

EXOSOMES
Exosomes: Preparation, Dosage & Safety
Prep: MSCs (typically umbilical cord or bone-marrow derived) are cultured under GMP conditions; conditioned media is collected and exosomes are isolated by ultracentrifugation, size-exclusion
chromatography, or precipitation kits. No standardized isolation method exists across products.
Dose/Volume: Dosing is reported in particle counts (commonly 10^9 - 10^11 particles per injection in published protocols) rather than a volume-based dose - there is currently no consensus standard.
Precaution: Product source, sterility testing, and characterization vary widely between suppliers - use only within an ethics-approved research protocol or registry.
SAFETY No large-scale, controlled human safety data exist yet. Theoretical concerns include immunogenicity from incompletely characterized cargo and variability in potency between
batches. Exosome therapy should not currently be offered as routine, evidence-based clinical care.

EXOSOMES
Exosomes: Overview from the Recent Literature
Wang Y, et al. J Transl Med. 2025;23:641.
Human umbilical cord MSC-derived exosomes reduced cartilage damage scores (OARSI
grading) from 6 to 1 in preclinical models, with early clinical data showing no adverse safety
signal.
Wang Z, et al. Front Pharmacol. 2025;16.
A systematic review of 28 preclinical studies found MSC-exosomes consistently improved
cartilage-protection and anti-inflammatory outcome measures in knee OA models.
Cell-Free Therapies for Chronic Pain review. 2025.
The MSC secretome shows preliminary analgesic efficacy across osteoarthritis, chronic low
back pain, and post-surgical pain models.
Song I, et al. Orthop J Sports Med. 2025.
Exosome size within a PRP preparation correlated with certain patient-reported outcomes at
12 weeks.

EXOSOMES
Exosomes: Clinical Status & Pearls
CLINICAL PEARL Standardization of exosome production, dosing, and delivery remains an unresolved challenge - batch-to-batch variability is a genuine limitation.
CLINICAL PEARL Preclinical evidence is genuinely strong; large-scale, controlled human trials are still lacking - teach exosomes as the field's most promising frontier, not a ready-for-practice
tool.
CLINICAL PEARL Where used clinically, exosome therapy should sit within a research protocol or registry with fully transparent, investigational-status informed consent.

NANOFAT
Nanofat: Definition & Mechanism
• Produced by mechanically emulsifying and filtering lipoaspirate into a fine, injectable micro-fat suspension - no enzymatic digestion
• Contains adipose-derived stromal and stem cells, growth factors, and a rich microvascular fraction
• Purely mechanical processing keeps nanofat within a more favourable regulatory category than enzymatically isolated SVF
CLINICAL PEARL Nanofat is a mechanically-prepared, minimally-processed cousin of SVF - simpler to produce chairside.

NANOFAT
Nanofat: Preparation, Dosage & Safety
Prep: Harvest 10-20 mL lipoaspirate via gentle syringe liposuction. Mechanically emulsify by shuttling between two syringes through a connector (Coleman/nanofat technique), then filter through
progressively finer mesh (typically 1200 to 600 to 400 micron) until it passes through a fine needle.
Dose/Volume: Injectable volume typically 1-3 mL per joint or soft-tissue target, via a 25-27G needle.
Precaution: Local adverse events (injection-site pain, transient swelling) are the most commonly reported issue; sterile technique at the harvest site is essential.
Parameter Detail
Harvest site Abdomen or flank, tumescent local anaesthesia
Typical course Single session; repeat based on clinical response
Contraindications Active infection, coagulopathy, insufficient adipose donor site

NANOFAT
Nanofat: Literature Overview & Clinical Use
Systematic review, nanofat in knee OA. Front Cell Dev Biol. 2025.
Clinical studies consistently reported pain relief and functional improvement with nanofat in
knee OA; adverse events limited to localized injection-site pain and inflammation.
SVF vs Nanofat RCT protocol. World J Exp Med. 2025.
An ongoing double-blinded randomized trial (Trichy, India) is directly comparing SVF and
nanofat for knee OA at 12 months using VAS, KOOS, WOMAC, and MRI cartilage mapping.
Curr Pain Headache Rep. 2024;28:27-35.
A review of orthopedic stem-cell approaches for OA management situates nanofat among current trends in minimally invasive regenerative joint care, flagging the need for standardized preparation
protocols.

ADIPOSE-DERIVED CELLS
Adipocytes & the Regenerative Role of Fat
Beyond Energy Storage
Mature adipocytes and adipose stroma secrete cytokines,
adipokines, and growth factors that actively influence local
inflammation and joint biology.
A Rich Autologous Source
Adipose tissue yields a substantially higher concentration of
stromal and progenitor cells per millilitre than bone
marrow, via a simple lipoaspirate.
The Adipose-to-Biologic Pipeline
Raw lipoaspirate can be processed toward nanofat
(mechanical) or SVF (enzymatic) depending on the desired
cellular concentration and regulatory pathway.

SVF
Stromal Vascular Fraction (SVF): Definition & Mechanism
• A heterogeneous cell population isolated from lipoaspirate via enzymatic (collagenase) digestion followed by centrifugation
• Contains adipose-derived stem cells, pericytes, endothelial progenitor cells, and immune cells in a single autologous preparation
• Delivered as a single intra-articular injection, typically same-day, point-of-care
CLINICAL PEARL Because enzymatic digestion is used, SVF preparation carries more regulatory scrutiny than nanofat or PRP in several jurisdictions.

SVF
SVF: Preparation, Dosage & Safety
Prep: Harvest 100-200 mL lipoaspirate under tumescent local anaesthesia. Digest with collagenase enzyme, wash, then centrifuge to pellet the stromal vascular fraction; resuspend in saline or platelet-
poor plasma prior to injection.
Dose/Volume: Injectable volume typically 2-5 mL per joint, with cell viability confirmation (>85%) recommended before injection where feasible.
Precaution: Enzymatic digestion introduces a regulatory and quality-control burden not present with PRP or nanofat - confirm your local legal pathway before offering SVF.
Parameter Detail
Harvest site Abdomen or flank, tumescent local anaesthesia
Typical course Usually single session; longer-term follow-up data exist to 2+ years
Contraindications Active infection, coagulopathy, malignancy, insufficient donor adipose volume

SVF
SVF: Literature Overview & Indications
Review with >2-year follow-up. Stem Cell Rev Rep. 2025;21(8).
A review of clinical SVF studies in OA with over two years of follow-up found consistent
improvement across imaging and functional scores (VAS, WOMAC, KOOS).
Injection of SVF rapidly relieves pain. MDPI. 2025.
In 151 knee OA patients (KL grade II-IV) followed for 1 year, intra-articular SVF injection was
associated with rapid pain relief.
Efficacy of SVF, single-arm trial. MDPI. 2025.
Using a standardized, laboratory-manufactured SVF product, this trial demonstrated
meaningful pain relief and functional improvement in symptomatic knee OA.
SPOST Study protocol (SVF + PRP). 2025.
An ongoing Phase 3 multicenter trial in Switzerland is directly comparing SVF and PRP for
knee OA.

STEM CELLS
Mesenchymal Stem/Stromal Cells: Concept & Sources
Source Typical Access Regulatory Note
Bone marrow (iliac crest) Point-of-care aspirate, moderate yield Minimally manipulated - broader regulatory latitude
Adipose tissue High yield via lipoaspirate
Enzymatic processing may cross into 'more than minimal
manipulation'
Umbilical cord / Wharton's jelly Allogeneic, high proliferative capacity Typically requires culture expansion - tightly regulated
CLINICAL PEARL The International Society for Cell & Gene Therapy prefers 'mesenchymal stromal cell' over 'stem cell' - most culture-expanded products appear to act through paracrine
signalling rather than true tissue engraftment.

STEM CELL THERAPY
Cultured Stem Cell Therapy in Practice: Ciplostem
An allogeneic, culture-expanded bone-marrow-derived mesenchymal stromal cell (BM-MSC) product, DCGI-approved in
India for knee osteoarthritis
Developed by Stempeutics Research and brought to market through Cipla - India's first approved cell-based therapy for
knee OA
Delivered as a single intra-articular injection of 25 million pooled, cultured allogeneic MSCs, co-administered with
hyaluronic acid
Positioned as a disease-modifying option for Grade II-III knee OA, with a reported benefit window of up to 2 years in
company Phase 3 data

STEM CELLS
Stem Cells: Dosage, Administration & Safety
Administration (Ciplostem example)
Prep: Single intra-articular knee injection of 25 million pooled, cultured allogeneic BM-MSCs, co-administered with hyaluronic acid as a carrier/adjunct in the same procedure.
Dose/Volume: One-time dose per treatment cycle; no repeat injection required within the studied benefit window (reported up to 2 years).
Precaution: As an allogeneic product, screen for hypersensitivity and confirm cold-chain storage/handling per manufacturer instructions; use only within approved indications (Grade II-III knee OA).
Parameter Detail
Autologous vs allogeneic Autologous (BMAC/adipose) avoids donor-matching concerns; allogeneic (Ciplostem) is 'off-the-shelf' but requires manufacturer-controlled
quality assurance
Pre-procedure workup Confirm diagnosis, imaging-graded OA severity, and exclude infection or malignancy at the injection site
Contraindications Active joint infection, known hypersensitivity to product components, pregnancy (per product-specific labelling)

STEM CELLS
Stem Cells: Broader Applications in Pain Medicine
Osteoarthritis
The most mature clinical application - intra-articular delivery for cartilage maintenance
and symptom relief.
Discogenic Pain
Intradiscal MSC delivery aiming to influence the degenerated disc's local biology.
Neuropathic Pain
Preclinical evidence supports MSC-mediated neuroinflammatory modulation; human
data remain early-stage.
Non-union / Bone Healing
Orthopedic application supporting fracture repair in delayed or non-union settings.

REGULATION
Regulatory Essentials for Pain Biologics
Minimal Manipulation
PRP, BMAC, and nanofat generally qualify as minimally processed - lighter regulatory
oversight in most jurisdictions.
Enzymatic Processing (SVF)
Collagenase digestion may cross into 'more than minimal manipulation,' triggering
stricter oversight depending on the country.
Culture-Expanded / Allogeneic Products
Laboratory-expanded MSC products (e.g., Ciplostem) are regulated as biologic drugs,
requiring formal approval pathways (DCGI, FDA, EMA).
Informed Consent
Explicitly document evidence level, investigational or off-label status, and cost -
essential across every biologic discussed today.

SUMMARY
Pain Biologics: Key Clinical Pearls
- PRP: leukocyte-poor for joints, leukocyte-rich for tendons; 3-8 mL typical volume - BMAC adds a marrow-derived cellular payload; harvest-site discomfort exceeds injection
discomfort
- Exosomes are the most exciting frontier - and the least standardized for dosing - Nanofat (mechanical) vs SVF (enzymatic): the processing method drives the regulatory
pathway
- Cultured, allogeneic products (e.g., Ciplostem) sit at the top of the regulatory ladder -
follow the product insert
- Across every biologic: standardize preparation, use ultrasound guidance, and counsel
honestly on realistic outcomes

CORTICOSTEROIDS
Corticosteroids: Mechanism of Action
1
Diffuse across the cell membrane and bind cytoplasmic glucocorticoid receptors
2
Translocate to the nucleus and modulate gene transcription of inflammatory mediators
3
Inhibit phospholipase A2 -> block the arachidonic acid cascade (prostaglandins & leukotrienes)
4
Reduce capillary permeability, leukocyte migration, and fibroblast activity at the injection site
5
Net effect: potent, reversible suppression of local and, with systemic absorption, distant inflammation

CORTICOSTEROIDS
Steroid Types & Properties
Agent Relative Potency Duration Particulate?
Methylprednisolone acetate Intermediate-High Intermediate Particulate
Triamcinolone acetonide Intermediate Intermediate-Long Particulate
Betamethasone (sod. phosphate + acetate) High Intermediate Mixed (small particle)
Dexamethasone sodium phosphate High Short-Intermediate Non-particulate
CLINICAL PEARL Particulate steroids have longer local residence and stronger anti-inflammatory effect, but carry a small risk of vascular occlusion if injected intravascularly. For cervical and
lumbar transforaminal epidural injections, prefer a non-particulate agent (dexamethasone).

CORTICOSTEROIDS
Steroids: Where We Use Them
Epidural Space: Transforaminal, interlaminar, or caudal - for radicular pain
Facet & SI Joints: Intra-articular for facetogenic or sacroiliac pain
Peripheral Joints: Knee, shoulder, hip - inflammatory or OA flares
Tendon Sheath / Bursa: Peritendinous, never intratendinous
Trigger Points: Myofascial pain, often with local anaesthetic
Peripheral Nerve Blocks: Adjunct for entrapment neuropathies

CORTICOSTEROIDS
Steroids: Typical Doses & Volumes by Site
Site Typical Steroid Dose Typical Total Volume
Cervical transforaminal epidural 4-6 mg dexamethasone 1-2 mL total
Lumbar transforaminal epidural 6-12 mg dexamethasone (or equivalent) 1.5-3 mL total
Interlaminar/caudal epidural 40-80 mg methylprednisolone equiv. 4-10 mL total (with saline/LA)
Facet or SI joint 20-40 mg triamcinolone/methylprednisolone 1-2 mL per joint
Knee / shoulder / hip 20-40 mg triamcinolone equivalent 1-3 mL per joint
Small joint / tendon sheath 5-10 mg triamcinolone equivalent 0.5-1 mL
SAFETY These are commonly taught reference ranges, not fixed prescriptions - always individualize by patient size, comorbidity, and institutional protocol, and use the lowest effective dose
consistent with your local guidelines.

SAFETY
Steroids: Technique, Safety & Contraindications
Match agent to anatomical risk Non-particulate steroid near any radicular/vertebral artery; particulate acceptable for peripheral joints.
Respect the re-injection interval No more than 3-4 joint injections per year at the same site, spaced >= 3 months apart.
Know the absolute contraindications Active infection, known hypersensitivity, uncontrolled bleeding diathesis.
Counsel on flare and systemic effects Transient flare (24-48h) is common; watch blood glucose in diabetics and bone density with repeated use.

HYALURONIC ACID
Hyaluronic Acid: Mechanism & Biological Rationale
A naturally occurring glycosaminoglycan and major structural component of healthy synovial fluid and cartilage extracellular matrix.
Viscosupplementation
Restores viscoelastic properties of synovial
fluid, improving lubrication and shock
absorption.
Chondroprotection
May reduce cartilage-degrading enzyme
activity and modestly downregulate local
inflammatory mediators.
Stimulates Endogenous Synthesis
Exogenous HA appears to stimulate
synoviocytes to produce more of the
body's own hyaluronic acid.
Mechanical + Biological Effect
Combines mechanical lubrication with a
milder biological anti-inflammatory action -
unlike a pure steroid.

HYALURONIC ACID
HA: Preparations & Indications
Preparation Class Molecular Weight Typical Regimen
Low molecular weight HA 500-730 kDa Series of 3-5 weekly injections
High molecular weight HA 6,000-7,000+ kDa Series of 3-5 weekly injections
Cross-linked (hylan G-F 20) Chemically stabilized, very high effective MW Single or 2-dose regimen
• Primary indication: mild-to-moderate knee osteoarthritis (KL grade 1-3); off-label use in hip, shoulder, ankle
• Ultrasound guidance improves accuracy for non-knee joints; aspirate any effusion before injecting
• Avoid mixing HA with local anaesthetic in the same syringe - may reduce viscosity and efficacy

HYALURONIC ACID
HA: Dosage & Administration Volumes
Joint Typical Volume per Injection Course
Knee 2-2.5 mL (linear) or up to 6 mL (cross-linked) 3-5 weekly, or single cross-linked dose
Shoulder 1-2 mL 3-5 weekly (off-label)
Hip (image-guided) 1-2 mL 1-3 sessions, image-guided
Small joints (hand/foot) 0.3-0.5 mL Individualized
SAFETY Aspirate the joint fully before injecting HA if an effusion is present - residual fluid dilutes the product and increases the risk of a post-injection inflammatory reaction. Confirm no
active infection before proceeding.

HYALURONIC ACID
HA: Clinical Pearls & Precautions
CLINICAL PEARL Warn patients upfront: benefit builds gradually over 2-4 weeks - this is not a same-day fix like a steroid injection.
CLINICAL PEARL A minority of patients develop an acute inflammatory 'pseudosepsis' reaction after HA - distinguish this from true septic arthritis before alarming the patient.
CLINICAL PEARL Some avian (rooster-comb) derived HA formulations carry a caution in patients with egg or poultry allergy; bacterial-fermentation-derived HA avoids this concern.
CLINICAL PEARL Avoid HA injection into a joint with active infection or a large undrained effusion - aspirate and reassess first.

SUMMARY
Key Takeaways
- Pain biologics span a spectrum - PRP and BMAC to nanofat, SVF, exosomes, and cultured
stem cells
- Preparation method (mechanical, enzymatic, or cultured) drives both dosing precision
and regulatory complexity
- Steroids remain the fastest tool - respect the particulate/non-particulate safety rule and
per-site dosing
- Hyaluronic acid lubricates the joint with a delayed but longer-lasting benefit
- Every biologic needs ultrasound precision, standardized preparation, and honest patient
counseling
- Match the tool - and its correct dose - to the biology of the problem, not the other way
around
Thank you - questions welcome

Comprehensive Overview of Pain Biologics, Steroids & Hyaluronic Acid in Pain Medicine